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In this study, we investigated analytical challenges associated with the formulation of 2 anti-HIV broadly
neutralizing antibodies (bnAbs), 3BNC117 and PGT121, both separately at 100 mg/mL and together at 50
mg/mL each. The bnAb formulations were characterized for relative solubility and conformational sta-
bility followed by accelerated and real-time stability studies. Although the bnAbs were stable during 4C
storage, incubation at 40C differentiated their stability profiles. Specific concentration-dependent ag-
gregation rates at 30C and 40C were measured by size exclusion chromatography for the individual
bnAbs with the mixture showing intermediate behavior. Interestingly, although the relative ratio of the 2
bnAbs remained constant at 4C, the ratio of 3BNC117 to PGT121 increased in the dimer that formed
during storage at 40C. A mass spectrometry-based multiattribute method, identified and quantified
differences in modifications of the Fab regions for each bnAb within the mixture including clipping,
oxidation, deamidation, and isomerization sites. Each bnAb showed slight differences in the levels and
sites of lysine residue glycations. Together, these data demonstrate the ability to differentiate degrada-
tion products from individual antibodies within the bnAb mixture, and that degradation rates are
influenced not only by the individual bnAb concentrations but also by the mixture concentration.
© 2018 Published by Elsevier Inc. on behalf of the American Pharmacists Association.2-4Introduction
The increasing use of passive immunization strategies to treat
unmet medical needs is delineating the need for coformulation and
codelivery of defined monoclonal antibody mixtures. Monoclonal
antibodies (Abs) are increasingly being developed for passive im-
munization strategies against multiple types of pathogens. This is
especially important due to the emergence of antibiotic-resistant
bacteria,1 long development timelines for prophylactic vaccines,2eat Valley Parkway, Malvern,
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lf of the American Pharmacists Asand the fragile nature of vaccine supply. Abs in development
include those against organisms targeted for biodefense such as
anthrax, plague, and botulinum toxin,5 the influenza surface
glycoprotein hemagglutinin,6 Abs against each of the virulence
components of anthrax,5,7 mAbs against ebola virus,8-12 filovirus,8
rabies,13,14 and human immunodeficiency virus (HIV).15-21 Associ-
ated with these pathogens is a high degree of genetic variability
such as that observed with the viral clades of the H5N1 virus22,23
and the multiple viral clades of HIV.24 This high degree of genetic
diversity, and in turn diversity in the structure of highly immuno-
genic surface-exposed antigens such as the influenza glycoprotein
hemagglutinin and the gp120 protein of HIV is combatted by our
immune systems with development of Abs with broad neutraliza-
tion abilities against multiple viral subtypes, termed broadly
neutralizing Abs (bnAbs).25,26 In contrast to bnAbs, many of the
monoclonal Abs developed for diseases such as inflammation, heart
disease, and cancer are highly specific for single epitope without
the mutational diversity observed for pathogens.27sociation.
A. Patel et al. / Journal of Pharmaceutical Sciences 107 (2018) 3032-3046 3033One promising approach for coformulation and codelivery of
mAbs for passive immunization is the use of multiple broadly
neutralizing anti-HIV monoclonal Abs (bnAbs), each targeting
different structural aspects of the gp120 coat protein. Animal
studies and clinical trials of bnAbs have demonstrated the need for
coinfusion of Abs against multiple targets of the immunogen to
prevent viral escape.16,28 For example, gp120 surface glycoprotein
of HIV is highly immunogenic at the CD4 binding site, across
multiple sites of the glycan shield, and the membrane proximal
external region.29 Viral escape occurs due to its continuing muta-
tional diversity. In some individuals though, disease has been held
in check through thematuration of multiple Abs that can neutralize
virus with a broad array of mutations at individual epitopes. These
include the bnAb 3BNC117 against the CD4 binding region of gp120,
the bnAbs 10-1074, and PGT121 against the V1/V2 glycan and the
bnAb PGDM1400 against the trimer apex of the HIV envelope.
Because these bnAbs cannot individually neutralize all genetic
variants of HIV, combinations of 2 or more bnAbs against different
epitopes have been suggested for neutralization of up to 99% of viral
clades.16
Today, approximately 75 monoclonal Abs have been commer-
cialized as biotherapeutics against a wide array of diseases.30 The
mAbs have been developed as single mAb entities with a typical
drug product (DP) containing a narrow range of excipients gener-
ally including a buffer, polyol or amino acid, a surfactant, and
possibly salts.31-33 Characterization of the DP includes assays for
potency, aggregation, fragmentation, and posttranslational modi-
fications (PTMs) such as oxidation, deamidation, isomerization, and
glycation. Typical assays include size exclusion chromatog-
raphy,34,35 visible and subvisible particle analysis,36,37 capillary
electrophoresis (CE)38 for clipping and ion-exchange chromatog-
raphy39 or capillary isoelectric focusing38 for PTMs. These chro-
matographic and electrophoretic methods, although classically
used tomonitor product quality during stability studies of biologics
are not able tomonitor changes at themolecular level. For example,
while clipping may be observed, the site of clipping cannot be
assessed by CE. In corollary, changes in the overall charge can be
assessed by ion-exchange chromatography, but the type and site of
modification cannot be assessed by the technique. To obtain this
information, successive steps of enzymatic digestion, followed by
chromatographic separation and mass spectrometric analysis have
been used to define modifications such as deamidation and
oxidation, and the site of degradationwithin the protein. Because of
analytical and instrumental complexities, this peptide mapping
technique has been used primarily for characterization purposes
and has only found limited use during routine DP stability studies.
Application of these commonly used analytical techniques to
coformulated Abs is more difficult to interpret. Coformulation of
Abs has only been carried out for a limited number of products
focused on polyclonal Abs and short term formulation studies of
monoclonal antibody-based products. Products such as intravenous
immunoglobulin40 are polyclonal in nature and multiple publica-
tion have described aggregation,41 fragmentation,42 and oxidation
of the Abs in mixtures.43 It is difficult to define the degradation
beyond the effect on classes of IgG, that is, idiotype/anti-idiotype
aggregate complexes, and how degradation of specific IgG’s af-
fects function is not possible. Degradation in known mixtures of
Abs is easier to interpret but has only been done in a limited
number of cases44-47 and only for short term stability studies. In a
series of studies using cation-exchange chromatography to sepa-
rate individual mAbs in a mixture, the effects of various stresses,
pH, salt, temperature, and vortexing were investigated. Precipita-
tion of the individual mAbs in the mixtures occurred by self-
association, with differing stabilities observed for each of the
mAbs.44 Glover et al. investigated the coformulation of Pertuzumaband Trastuzumab, 2 IgG1 mAbs, in an intravenous infusion bag
containing 0.9% sodium chloride and found similar stability trends
for the mixture versus the same mAbs alone following incubation
at 30C for 24 h.47 Similar to the intravenous immunoglobulin
products, the majority of the analytical techniques, except for ion-
exchange chromatography, did not distinguish between the mAb
species within the mixture.
In the studies described here, our 2 main goals were (1) to
demonstrate that coformulated mAbs could be formulated and
stored under conditions commonly used for commercial mAbs
during long-term storage; and (2) to demonstrate the utility of the
multiattribute method (MAM)48 for characterizing degradation
products in singly and coformulated mAb mixtures. The first goal is
important for developing platform formulations for use in early
clinical trials allowing for faster movement to the clinic and
reduction in development costs. The second goal drives us toward a
molecular level characterization of mAb stability during storage, an
area that has been lacking for mixture studies. Toward our first goal,
we first examined the relative solubility profile (using a poly-
ethylene glycol [PEG] precipitation assay) and conformational sta-
bility (using differential scanning calorimetry [DSC]) to establish
some baseline physical properties of the bnAb formulations. Using
accelerated and real-time stability studies, we then show that
coformulated mAbs are stable in an acetate/sucrose/polysorbate
formulation at 100 mg/mL, and that the degradation of the mAbs in
themixture approximated that seen for the individually formulated
mAbs. Along with the more standard analytical tools such as size
exclusion high-performance liquid chromatography (SE-HPLC),
microflow imaging, dynamic light scattering, and CE-sodium
dodecyl sulfate (CE-SDS), we used the mass spectrometry-based
MAM to gain molecular level characterization of degradants,
identifying deamidation, isomerization, glycation, and oxidation
sites specific to each mAb in the mixture within the Fv region.
Because both molecules were IgG1, we were not able to differen-
tiate when modifications, in the constant domains, were specific to
either molecule. An added difficulty to these mixtures is charac-
terizing components of the aggregates. Toward that end, we used
the MAM technique to quantify the relative levels of each bnAb in
the mixture and identify PTMs associated with the aggregated
bnAbs. Together, these data demonstrate that complex mixtures of
mAbs can be characterized at the molecular level providing greater




The 3BNC117 bnAb was the kind gift of Dr. Michel Nussenzweig
(Rockefeller University, New York, NY) and the PGT121 bnAb was
the kind gift of Dr. Dan Barouch (Harvard University, Boston, MA).
Frozen stocks of 3BNC117 (extinction coefficient 1.69 [(mg/mL)-1
cm-1]) and PGT121 (extinction coefficient 1.72 [(mg/mL)-1 cm-1]) at
~100 mg/mL, each were prepared at Just Biotherapeutics (Seattle,
WA) and sent to the University of Kansas for vialing and stored
at 80C. A mixture of 3BNC117 and PGT121 (extinction coefficient
for mixture 1.69 [(mg/mL)-1 cm-1]) was prepared by mixing the 2
stock bnAbs, each formulated in 20 mM acetate, 9% sucrose, 0.01%
w/v polysorbate 80 (PS80) pH 5.2 (ASu), at a 1:1 volume ratio. The
details of the composition of each bnAb formulation are listed in
Table 1. Most chemicals and reagents were purchased from Fisher
Scientific (Fair Lawn, NJ) and Sigma Aldrich (St. Louis, MO). Sucrose
was purchased from Pfanstiehl (Waukegan, IL). All the buffers and
themobile phase for SE-HPLCwere prepared using deionizedwater
from Water Pro PS Station (Labconco, Kansas City, MO) and were
Table 1





3BNC117 104 ± 2 20 mM Acetate with 9% sucrose and
0.01% w/v polysorbate 80, pH 5.2PGT121 121 ± 1
3BNC117 þ PGT121 117 ± 1
The bnAb coformulation contained a 1:1 (w/v) mixture of each protein.
A. Patel et al. / Journal of Pharmaceutical Sciences 107 (2018) 3032-30463034sterile filtered afterward using a 0.2 mm filter. CE-SDS gel separation
buffer, SDS-MW sample buffer, 0.1N NaOH, 0.1N HCl, and MW size
protein standards were purchased from Beckman Coulter. ß-mer-
capto-ethonal was purchased from Amresco (Solon, OH).Methods
PEG Precipitation Assay
The PEG precipitation assay was performed as previously
described.49 Briefly, stock solutions of PEG-10,000 ranging from 0%
to 40% (w/v) were prepared in 2 different buffers: (1) 20 mM ace-
tate with 9% sucrose and 0.01%w/v polysorbate 80, pH 5.2 (ASu),
and (2) 20 mM sodium phosphate, 150 mM sodium chloride pH 7.2
(PBS). Two hundred microliters of each PEG-10,000 solution was
added to a 96-well polystyrene plate with filter at the bottom
(Corning Life Sciences, Corning, NY) in triplicate. Individual or
mixture bnAb solutions were diluted to 1 mg/mL, using either their
respective formulation buffer or PBS, and then 50 mL of the diluted
samples were added to the wells to achieve final protein concen-
trations of 0.2 mg/mL. The plates were incubated overnight at room
temperature and then centrifuged at 3500  g for 15 min. The
filtrate was collected in a clear 96-well collection plate (Greiner
Bio-One North America Inc., Monroe, NC). Two hundred microliters
of the filtrate was transferred into a 96-well ultraviolet (UV) Star
microplate (Grenier#655801) and the absorbance at 280 nm of
each well was measured using SpectraMax M5 UVvisible plate
reader (Molecular Devices LLC, Sunnyvale, CA). The concentration
of each bnAb was calculated using their respective extinction co-
efficient (Table 1). The concentration of bnAb versus PEG-10,000
percentage was fit using a standard 4-parameter modified hill-








Where, t¼ top plateau, b¼ bottom plateau, mid ¼ x-axis midpoint,
and s ¼ slope. The %PEGmidpt values and apparent solubility value
parameters were then calculated from the resulting curve fit as
described in detail elsewhere.49Differential Scanning Calorimetry
DSC thermograms for bnAbs were collected using an Auto-VP
capillary differential scanning calorimeter (MicroCal/GE Health
Sciences, Pittsburgh, PA). Thermogramswere recorded from 10C to
110C at a scan rate of 1C/min. The bnAb samples were prepared in
20 mM acetate with 9% sucrose and 0.01% w/v polysorbate 80, pH
5.2 at concentration of 0.1 mg/mL and the experiment was per-
formed in triplicate. A buffer baseline was subtracted from each
bnAb thermogram and the data were normalized using Microcal
DSC software in Origin 7.0. The peaks were fitted using mathe-
matical model fit in Origin 7.0 to calculate the values of thermal
onset temperature (Tonset) and thermal unfolding temperature (Tm).Real-Time and Accelerated Stability Study
For accelerated and real-time stability studies, 200 mL or 1 mL of
each bnAb, either individually or in a 1:1 mixture, were dispensed
into 1.0 mL or 2.0 mL (13 mm) glass vials and sealed with FluroTec-
coated rubber stoppers and aluminum caps (West Pharmaceutical
Services, Exton, PA). Vials containing protein or formulation buffer
alone (in duplicate) were stored in the dark at up to 5 temperatures
(80C, 20C, 4C, 25C, 30C, and 40C) for up to 12 weeks. At
each indicated time point, vials were visually inspected and then
analyzed. For those vials containing a 1 mL sample volume, time
points were analyzed by repeated sampling from a single vial.
Neutralization Activity Assay
Neutralization titers of monoclonal Abs were determined using
a luciferase-based assay in TZM.bl cells as previously described.50,51
Briefly, mAb samples were tested using a primary concentration of
25 mg/mL with 5-fold serial dilutions against a panel of 10 HIV-1
Env pseudoviruses that were selected for being either 3BNC117
sensitive/PGT121 resistant or 3BNC117 resistant/PGT121 sensitive.
This allowed for the measurement of neutralizing activity of single
Abs in samples containing a mixture of both 3BNC117 and PGT121.
Antibody titrations were incubated with HIV-1 Env pseudoviruses
for 1 h at 37C, and TZM.bl cells were then added in growth media
containing DEAE-dextran at a final concentration of 11 mg/mL.
Assay plates were incubated for 48 h at 37C, 5% CO2, and luciferase
reporter gene expressionwas measured using Bright-Glo luciferase
reagent (Promega) and a Victor 3 luminometer (Perkin Elmer).
Neutralization titers (50% and 80% inhibitory concentrations, IC50
and IC80, respectively) were calculated as themAb concentration at
which relative luciferase units (RLU) were reduced by 50% or 80%
compared to RLU in virus control wells after subtraction of back-
ground RLU in cell control wells. All assays were performed in a
laboratory meeting good current laboratory practice standards.
Size Exclusion High-Performance Liquid Chromatography
Before SE-HPLC, bnAb samples were diluted 100-fold using their
respective formulation buffers and then centrifuged at 14,000 g for
5 min. Forty microliters of each sample was subjected to SE-HPLC
using a Shimadzu HPLC system equipped with a photodiode array
detector (Shimadzu, Columbia, MD) and a TSKgel G3000SWx1
stainless steel column and TSKgel SWxI guard column (Tosoh Bio-
sciences, San Francisco, CA). The mobile phase consisted of 0.2 M
sodium phosphate (pH 6.8) set at a flow rate of 0.7 mL/min. The
columnandautosamplerwereoperated at30Cand4C, respectively.
Gelfiltration standards (Biorad Laboratories, Hercules, CA)were used
to ensure HPLC, column integrity, and separation efficiency. Protein
elution was monitored using an absorbance of 214 and 280 nm, and
protein peaks were quantified using the LC Solution software (Shi-
madzu Corporation) as described in detail elsewhere.35 In addition,
the sampleswere subjected to SE-HPLCwithout the column attached
to better determine if larger aggregates are present in the samples or
if the sample binds to the column (i.e., sample recovery).
Monomer and dimer peak fractions were collected using a
Dionex (Sunnyvale, CA) Ultimate 3000 system equipped with a
Waters (Milford, MA) XBridge BEH 200A column and a mobile
phase of 100 mM sodium phosphate, 250 mM sodium chloride, pH
6.8. Peak fractions were purified after SE-HPLC separation by col-
lecting fractions shortly after traveling through the HPLC detector;
the duration of fraction collection was determined manually by
monitoring the real-time signal display using Chromeleon software
(Thermo Scientific,Waltham,MA). Fractions were buffer exchanged
into 20 mM sodium acetate pH 5.5 and concentrated using a Cen-
tricon spin concentrator with a 30 kDa molecular cutoff. To confirm
Figure 1. PEG precipitation of individual or 1:1 bnAb mixture formulated in PBS or ASu (see Methods for complete formulation compositions). PEG precipitation of (a) 3BNC117 and
PGT121 in PBS and ASu formulation; (b) Individual or 1:1 mixture of 3BNC117 and PGT121 in ASu formulation. Error bars denote standard deviation from triplicate experiments. See
Table 1 for composition of formulations. 3BNC117 at 100 mg/mL in ASu: solid black squares; 3BNC117 at 100 mg/mL in PBS: open black squares; PGT121 at 100 mg/mL in ASu: solid
red circles; PGT121 at 100 mg/mL in PBS: open red circles; Coformulation of 3BNC117 and PGT121 each at 50 mg/mL in ASu: solid green triangles.
A. Patel et al. / Journal of Pharmaceutical Sciences 107 (2018) 3032-3046 3035purity of the collections, 5 mL was analyzed by SE-HPLC and over-
layed with the starting material.
CE Sodium Dodecyl Sulfate
Formulatedmonoclonal antibody solutions were diluted to 1mg/
mL with a mixture of 5.6% ß -ME in SDS-MW sample buffer. Samples
were heated in Eppendorf tubes at 70C for 10 min and then
transferred to PCR vials. CE analysis was performed using a Beckman
PA800 instrument equipped with a UV diode-array detector (Beck-
man Corporation, Brea, CA). A bare-fused capillary with a total length
of 30.2 cm, effective length of 20.2 cm, and an inner diameter of 50
mmwas used for separation. The running conditions are described in
the Beckman Coulter manual for IgG Heterogeneity kit.
Multiattribute Peptide Mapping Method
The workflow for the MAM involves characterizing a mono-
clonal antibody using MS2 to identify the modifications on the
antibody using an MS2 capable MS (Thermo Scientific Q Exactive
HF Biopharma). Next a Pinpoint workbook is created for each of the
modification that will bemonitored. Once the Pinpoint workbook is
created, the MS data only need to be collected in MS1mode or with
an MS1 only MS. Initially, the PTMs on the 3BNC117 antibody and
PGT121 were characterized using data acquired on a Thermo Sci-
entific Q-Exactive HF Biopharma mass spectrometer. These data
were searched with Biopharma Finder (Thermo Scientific).
Sample Preparation
The reduction, alkylation, and trypsin digestion of bnAb samples
were performed as previously described in Rogers et al.48 and then
analyzed as described below.Table 2
Apparent Solubility and PEGmidpt Values of 2 Individual bnAb’s in Different Formulation
(n ¼ 3)






3BNC117 þ PGT121 ASu 2
N.D., Could not be determined due to nonliner nature of experimental data (see text).
a Statistical significance compared to the PGT121 in PBS buffer with a p value <0.05, dReversed-Phase LC
A Thermo Vanquish Dual Column UPLC (Thermo Fischer Scien-
tific, Waltham, MA) was used for these experiments. Mobile phase
A contained 0.1% formic acid inwater andmobile phase B contained
0.1% formic acid in 100% acetonitrile. The following LC conditions
were used: flow rate 0.25 mL/min, column temperature 50C dur-
ing the separation, and the autosampler was kept at 6C. For sep-
aration analysis, a nominal load of 2 mg of the digest, based on final
sample concentration, was injected onto a Zorbax C18 300-SB, 300
A pore size, 1.8 mm particle, 2.1 mm  150 mm column (Agilent).
The gradient started at 1% B until 5 min, then increased gradually to
10% in 1min. Next, the gradient was ramped up from 10% B to 35% B
in 70 min. From 70 to 75 min, the %B was increased to 60%. At
75.1 min, the %B was reduced to 1% until minute 80. Total run time
per sample was 80 min. The wash and re-equilibration pump was
running in parallel to the gradient pump. The wash and re-
equilibration pump employs 5 “saw tooth” ramps up to 90% B,
holds at 90% B, and then ramps back down to 1% B.Mass Spectrometry
The tryptic peptides were separated and monitored by RP-HPLC
coupled to MS (Thermo Scientific Q Exactive HF BioPharma;
Thermo Fisher Scientific, Waltham, MA). The MS capillary tem-
perature was maintained at 250C with an S-lens RF level at 50. The
MS spectra collection was performed at 120,000 resolution in
positive polarity mode with an AGC target of 3E6, maximum ion
time of 200 ms, and a scan range of 300 to 1800 m/z between 5 to
70 min run time. Accurate mass measurement of the electrospray
ionization was monitored using a lock mass of 391.2843 (diisooctyl
phthalate). The MS2 spectra were acquired with the following
conditions. The resolution was set at 15,000. One microscan was
acquired with the AGC target set at 1e5. The maximum ion times, and the Mixture in One Formulation, as Measured by the PEG Precipitation Assay
PEGmidpt (w/v) Apparent Solubility (mg/mL)
ean ± 1SD Mean ± 1SD p Value
.5 ± 0.1 33 ± 3 <0.01a
9.0 ± 0.0 N.D. e
0.3 ± 0.1 55 ± 6 e
2.1 ± 0.0 N.D. e
6.4 ± 0.0 N.D. e
etermined using student t-test.
Figure 2. Representative DSC thermograms of individual or 1:1 bnAb mixture. See
Table 1 for composition of formulations. See Table 3 for a summary of the thermal
onset and thermal unfolding values calculated from the DSC thermograms. 3BNC117 at
100 mg/mL in ASu: solid black squares; PGT121 at 100 mg/mL in ASu: solid red circles;
Coformulation of 3BNC117 and PGT121 each at 50 mg/mL in ASu: solid green triangles.
DSC thermograms were offset for easier visualization.
A. Patel et al. / Journal of Pharmaceutical Sciences 107 (2018) 3032-30463036was 250ms. A top 5methodwas usedwith the normalized collision
energy set at 26. The charge exclusionwas set to ignore unassigned
charge ions and ions that had a charge greater than 8. The dynamic
exclusion was set to 10 s.
Search Parameters
The raw files from the Q Exactive HF Biopharma mass spec-
trometer were searched using Biopharma Finder (Thermo Scienti-
fic). The MS2 spectra were searched against the antibody sequence
and trypsin. The default search parameters were used except that
themaximumpeakwidth was increased to 3.2min. A variablemass
search was also performed from 58 to 162. Carboxymethylation
was set as a static modification. CHO glycans, oxidation, deamida-
tion, hydroxylation, glycation, H2O loss, and NH3 loss were set as
variable modifications.
MAM Analysis of the Dimer and Monomer SEC Fractions
The enriched dimer and monomer fractions were prepared for
MAM analysis as described above. The data were also acquired
similarly. To determine if the dimer fraction was different from the
monomer fraction, peptides from the variable region, from each
molecule, were examined. The area for each peptide was compared
to a constant domain peptide. Three variable domain peptides for
3BNC117 were compared to 5 constant domain peptides. Six vari-
able domain peptides for PGT117 were compared to 5 constant
domain peptides. Ratios were calculated for each fraction and then
the average fold enrichment was calculated.
Results
Apparent Solubility and Conformational Stability of bnAbs
The relative apparent solubility profile of each bnAb sample was
measured as a function of PEG concentration. For 3BNC117 and
PGT121 in PBS buffer, a sigmoidal dose-response curve was
observed for each bnAb (Fig.1a). Using a 4-parameter modified hill-
slope to fit both curves of 3BNC117 and PGT121 in PBS, % PEG
midpoint values of 8.5% and 10.3% and relative apparent solubility
values of approximately 33 and 55 mg/mL, respectively, were
determined for the bnAbs 3BNC117 and PGT121 (Table 2). As also
shown in Figure 1a, the %PEG versus protein concentration profiles
of 3BNC117 in 2 different solutions (PBS buffer or ASu formulation)
were distinct. A higher concentration of PEG was required to pre-
cipitate 3BNC117 in ASu compared to the bnAb in PBS, indicating a
higher relative apparent solubility in the acetate-based formula-
tions. Moreover, 3BNC117 in ASu did not completely precipitate out
of solution at the highest PEG concentration tested (40% w/v). The
PEG precipitation profile of 3BNC117 was also different between
PBS buffer and the ASu formulation. The sigmoidal curve of the
3BNC117 bnAb as a function of PEG concentrationwas not observed
when the protein was in ASu formulation. A gradual decrease in
soluble protein was observed at lower PEG concentrations (0%-
25%), which prevented the use of previously describedmodels to fit
the data. Therefore, the relative solubility profiles of 3BNC117 in
PBS buffer versus ASu formulations were compared using the PEG
concentration at which 50% of the protein had precipitated out of
solution (PEGmidpt). As shown in Table 2, the PEGmidpt value was
higher for 3BNC117 in ASu (29% PEG) compared to the protein in
PBS (8.5% PEG). The %PEG versus protein concentration profiles of
PGT121 in both the PBS or ASu formulations showed overall similar
trends to the observations of 3BNC117 with a few distinctions
(Fig. 1a). The PGT171 displayed higher PEG midpoint and apparent
solubility values in PBS buffer compared to 3BNC117 in PBS buffer
but had lower PEG midpoint values, compared to 3BNC117, in the
ASu formulation.Interestingly, the %PEG versus protein concentration profile of 2
bnAb’s in a 1:1 mixture in the ASu formulation was observed to be
in between the values seen for the 2 individual proteins (Fig. 1b).
Similarly, the corresponding PEGmidpt value of the mixture (26.4%
PEG) was also in between the 2 individual bnAbs (22.1% and 29.0%
PEG). Thus, the PEG precipitation assay distinguished between the
3 samples with the mixture behaving as a composite of the 2 in-
dividual components in the ASu formulation.
DSC was used to examine the conformational stability of the 3
bnAb samples. Representative DSC thermograms comparing the in-
dividual bnAbs with the mixture are shown in Figure 2. Both bnAbs
displayed at least 3 thermal unfolding events, with the major ther-
mal melting transition temperatures (Tm1, Tm2, and Tm3) having
been shown previously to represent the unfolding of the CH2
domain, Fab, and CH3 domains, respectively, of IgG molecules.52,53
Interestingly, a different and distinct profile of the thermograms
was observed for each of the bnAb samples. First, the initial thermal
transition, the onset unfolding temperature (Tonset), was determined
for each sample54,55 as shown in Figure 2 and Table 3. The calculated
Tonset value of the bnAb mixture was similar to PGT121 (~61.3C),
which were both slightly lower than 3BNC117 (~62.6C). Second, we
compared the 3 major thermal unfolding temperature values (Tm1,
Tm2, and Tm3) as shown in Figure 2 and Table 3. PGT121 showed a
large initial unfolding transition (Tm1) followed by 2 smaller transi-
tions (Tm2, Tm3), whereas 3BNC117 displayed 1 small unfolding
transition (Tm1) followed by 1 large (Tm2) and 1 small transition
(Tm3). The differences in the observed thermal profiles are likely
attributed to structural differences between the 2 bnAbs. In the case
of the bnAb mixture, 2 large and heterogeneous thermal transitions
were observed, which appeared to overlap with the major transi-
tions of the 2 individual bnAb thermograms (i.e., Tm1 in PGT121-
alone and Tm2 in 3BNC117-alone). The calculated Tm values in the
bnAb mixture, however, were somewhat different than 3BNC117- or
PGT121-alone (Table 3), a difference possibly due to the contribu-
tions within the mixture of the minor transitions in the individual
Table 3
Conformational Stability of bnAbs Samples as Indicated by Thermal Onset Tem-
perature Values (Tonset) and Thermal Melting Temperature (Tm1, Tm2, and Tm3)
Values as Measured by DSC
bnAb Tonset (C) Tm1 (C) Tm2 (C) Tm3 (C)
3BNC117 62.6 ± 0.4 70.6 ± 0.0 80.7 ± 0.0 97.1 ± 0.1
PGT121 61.3 ± 0.0 68.2 ± 0.0 76.2 ± 0.0 83.6 ± 0.0
3BNC117/PGT121 61.4 ± 0.3 68.6 ± 0.0 81.1 ± 0.0 e
See Table 1 for composition of each bnAb formulation.
See Figure 2 for representative thermograms for each bnAb formulation.
Results are presented as Avg ± SD.
All experiments were performed in triplicate.
A. Patel et al. / Journal of Pharmaceutical Sciences 107 (2018) 3032-3046 3037bnAbs. Furthermore, the 50% lower concentration of 3BNC117 in the
bnAb mixture possibly resulted in the inability to quantify Tm3 that
was observed in 3BNC117-alone. Overall, since the Tonset and Tm1
values reflect the initial structural alterations of the bnAb molecules
versus temperature and are likely the most important in terms of
assessing the stability of the proteins from a formulation point of
view, 3BNC117 appeared slightly more conformational stable
compared to PGT121 as a function of temperature, and mixing the 2
bnAbs together did not appear to notably effect the inherent stability
(Tonset and Tm1 values) of either protein.
Real-Time and Accelerated Stability
The activity of the Abs was measured in the single and cofor-
mulated mixtures after 8 weeks of incubation. The data are pre-
sented in Table 4. To measure the functional neutralizing activity of
each individual antibody in the mixture 2 virus panels were
selected, 1 specific for the 3BNC117 bnAb and another representa-
tive panel specific for the PGT121 bnAb allowing us to interrogate
the activity of each bnAb within the coformulated mixture without
purifying the individual Abs. Values that are within 3-fold of the
control are considered concordant by the assay validation criteria. A
loss of activity would be an increase in the IC50 or IC80 greater than
3-fold of the control. The activity was corrected to account for theTable 4
Neutralization Activity of 3BNC117, PGT121, and the 3BNC117/PGT121 Mixture to HIV Pse
3BNC117 Virus Sensitive Panel Titer in TZM.bl Cells (mg/mL)
Q461.e2 C2101.c01
IC50 IC80 IC50 IC80
PGT121 4C >25 >25 >25 >25
3BNC117 4C 0.051 0.167 0.020 0.106
PGT121/3BNC117 4C 0.063 0.211 0.022 0.177
PGT121 25C >25 >25 >25 >25
3BNC117 25C 0.039 0.136 0.015 0.084
PGT121/3BNC117 25C 0.044 0.201 0.019 0.118
PGT121 Control >25 >25 >25 >25
3BNC117 Control 0.057 0.196 0.028 0.115
PGT121 Virus Sensitive Panel Titer in TZM.bl Cells (mg/mL)
1394C9G1 (Rev-) ZM247v1 (Rev-)
IC50 IC80 IC50 IC80
PGT121 4C 0.759 7.011 0.011 0.049
3BNC117 4C >25 >25 >25 >25
PGT121/3BNC117 4C 0.476 4.852 0.013 0.057
PGT121 25C 0.721 6.606 0.019 0.063
3BNC117 25C >25 >25 >25 >25
PGT121/3BNC117 25C 0.533 5.576 0.021 0.067
PGT121 Control 0.662 6.853 0.015 0.051
3BNC117 Control >25 >25 >25 >25
Antibodies against a panel of viruses that included 5 3BNC117 sensitive/PGT121 resi
measuring 3BNC117 or PGT121, respectively).
All values are the average of duplicate measurements.lower concentration of individual bnAbs in the mixture as
compared to the singly formulated bnAbs. As evidenced by the
data, both Abs and the mixtures show full activity after 8 weeks
following storage for 8 weeks at 25C and at 4C.
To better understand the aggregation propensity of the bnAbs
during storage, individual bnAbs in ASu, and in a 1:1 mixture in ASu,
were incubated at 5 temperatures (80C, 20C, 4C, 25C, and
40C) for up to 12 weeks. The oligomeric state of each sample was
monitored using SE-HPLC and compared to a control (day 0).
Representative chromatograms of 3BNC117 or PGT121 (individually
and in a 1:1 mixture) after 12 weeks of incubation are shown in
Figure 3. In addition to a monomer species, higher (e.g., dimers,
multimers) and lower (e.g., fragments) molecular weight species
were observed, which were more abundant at the higher incubation
temperatures. The areas of each of these species observed in the SEC
chromatograms were quantified and plotted relative to the Day
0 control. Each of the bnAb formulations contained primarily
monomerwith small levels of aggregates and fragments at time zero.
The relative distribution of the individual species (monomer, dimer,
etc.) did not change in the 80C, 20C, and 4C samples over 12
weeks (data not shown). As expected, the loss of each bnAb mono-
mer was accelerated at 40C (Fig. 4a) compared to 25C
(Supplemental Fig. S1A), and a concurrent increase in the abundance
of the higher and lower molecular weight species (Figs. 4b-4d and
Supplemental Fig. S1B-S1D) was observed. After 12 weeks of incu-
bation at 40C, the relative monomer area decreased by ~8% and ~6%
for 3BNC117 and PGT121 in ASu, respectively. Interestingly, although
3BNC117 primarily formed dimers during storage (~6% increase
compared to day 0 at 40C), the PGT121 formed more complex
multimer species (~3% increase compared to day 0 at 40C).
The relative monomer loss and the formation of multimers/di-
mers in the bnAb formulations alone and in mixtures were further
investigated in an additional stability study inwhich each bnAbwas
formulated alone at 50 mg/mL and 100 mg/mL and together with
both bnAbs coformulated at 50 mg/mL each in the mixture for a
final total protein concentration of 100 mg/mL. Aliquots at each
timepoint were removed from the same vial throughout the studyudovirus Panel Following 8 Weeks Incubation at Either 4C or 25C
C4118.c09 R3265.c06 ZM249M.PL1
IC50 IC80 IC50 IC80 IC50 IC80
>25 >25 >25 >25 >25 >25
0.036 0.155 0.079 0.692 0.028 0.129
0.040 0.253 0.072 0.927 0.031 0.139
>25 >25 >25 >25 >25 >25
0.032 0.136 0.117 0.921 0.031 0.134
0.031 0.188 0.109 1.361 0.039 0.232
>25 >25 >25 >25 >25 >25
0.052 0.215 0.204 1.513 0.055 0.243
Du422.1 377.v4.c9 Ce1172_H1
IC50 IC80 IC50 IC80 IC50 IC80
0.013 0.053 0.322 1.099 0.005 0.020
>25 >25 >25 >25 >25 >25
0.014 0.067 0.351 1.188 0.009 0.032
0.011 0.055 0.283 0.991 0.005 0.017
>25 >25 >25 >25 >25 >25
0.019 0.065 0.381 1.308 0.007 0.024
0.010 0.048 0.371 1.284 0.007 0.028
>25 >25 >25 >25 >25 >25
stant isolates and 5 3BNC117 resistant/PGT121 sensitive isolates (for specifically
Figure 3. Representative SE-HPLC chromatograms of bnAbs monitored at 214 nm showing formation of aggregates and fragment species with respect to different temperatures
(4Ceblack; 25Cepink; and 40Ceblue) at 12 weeks (a) 3BNC117ASu, (b) PGT121ASu, and (c) Mixture of 3BNC117 and PGT121 in ASu. See Table 1 for composition of formulations.
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seen in Figure 5, the rates of dimer and multimer formation for the
individually formulated bnAbs were severely reduced for both
bnAbs when formulated at 50 mg/mL as compared to 100 mg/mL
with 3BNC117 primarily forming dimer and PGT121 primarily
forming oligomer at 40C. In the mixture, the concentration of
dimer at each timepoint was nearly identical to that of the indi-
vidually formulated 3BNC117 at 50 mg/mL. Similarly, the concen-
tration of oligomer at each timepoint matched that for the
individually formulated PGT121 at 50 mg/mL suggesting that the
aggregation of each bnAb in the mixture is independent of the
other. At 30C only dimer formation occurred with no discernable
increase in oligomeric species for either antibody (data not shown).
The amount of low molecular weight species was quantified for
selected samples by monitoring the heavy chain (HC) and light chain
(LC) peak purity by rCE-SDS. Representative electropherograms of
3BNC117, PGT121, and the 1:1mixture are shown in Figure 6. Distinct
differences are apparent for both the HC and LC profiles of the
electropherograms between the singly formulated bnAbs. Hetero-
geneity of the 3BNC117 LC and the PGT121 HC resulted in multiple
peaks in the time 0 control samples, which did not change over time.
The heterogeneity is likely due to glycosylation, for example,
3BNC117 LC (Fig. 6a, 16-17 min) has a consensus glycosylation site at
Asn KV:90 that is at least 90% occupied based on analysis by MAM
(unpublished results). The PGT121 HC (Fig. 6b, 20-21 min) has 3
consensus glycosylation sequences, Asn HV:79, Asn HV:141, and Asn
Fc-N:74. Based on MAM analysis, the Asn at HV:141 and Fc-N:74 are
at least 99% occupied, whereas the site at Asn HV:79 is not occupied
to any measurable degree. Clipped species of various molecularweights were observed at elevated temperature as compared with
the time 0 control. Specieswere integrated in 3 groups (low,mid, and
highMW) depending on themigration time relative to the LC and HC
peaks. LowMW refers to species eluting earlier than the LC from 13-
16min, andmidMWrefers to species eluting between the LC andHC
at 17-19 min for 3BNC117 and 16.5-20 min between for PGT121, but
not including the nonglycosylated species. The relative areas of each
groupwere quantified and plotted as a function of incubation time in
Figure 7and Supplemental Figure S2. Despite different purity levels
at time 0, the rate of loss appears to be similar between the samples.
LowMWclipped species form at a higher rate in the 3BNC117 sample
compared with the PGT121 sample. The 1:1 mixture has a rate
similar to the 3BNC117 sample. This trend was reversed in the mid
MWclipped specieswhere the PGT121 sample has a higher rate than
the 3BNC117 and 1:1 mixture sample. However, clipped species
observed in each of the singlemolecule formulations comigrate with
the LC regions of the mixture. The low MW species between 15 and
16 min in the 3BNC117 sample comigrates with the LC of PGT121 in
the 1:1 mixture sample. The mid MW species at 17 min in the
PGT121 sample comigrates with the 3BNC117 LC in the mixture.
MAM Data
The primary sequence coverage as determined by the MAM
mass spectrometry based analysis (see Methods) for the LC and HC
of the single formulation of the 3BNC117 molecule were 96.1% and
96.7%, respectively. The primary sequence coverage for the LC and
HC of the single formulation of the PGT121moleculewere 100% and
96.3%, respectively. The primary sequence coverage for the variable
Figure 4. Percent amount of monomer, aggregates (dimers and multimers), and fragments as a function of time for bnAb formulations in ASu formulation following incubation at
40C up to 12 weeks as measured by SE-HPLC. Data are plotted as mean ± SD with n ¼ 4. See Table 1 for composition of formulations. 3BNC117 at 100 mg/mL in ASu: solid black
squares; PGT121 at 100 mg/mL in ASu: solid red circles; Coformulation of 3BNC117 and PGT121 each at 50 mg/mL in ASu: solid green triangles. (a) Percent decrease in monomer vs.
time, (b) percent dimer formation vs. time, (c) percent multimer formation vs. time, (d) percent fragmentation vs. time.
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the single formulations. The common PTMs, including deamida-
tions, glycation, isomerization, and oxidation, observed between
the single formulations and the coformulation are shown in
Figure 8a. Low level deamidation, glycation, and oxidation occur
within the common constant regions of the bnAb molecules. In
addition, there are many aspartic acid residues that are common
between 2 molecules, and 3 of the aspartic acid residues showed
low levels of isomerization, whereas aspartic acid Hinge:108 is
significantly isomerized in each formulation when the molecules
are stressed. Figures 8b and 8c show specific modifications for
3BNC117 and PGT121, respectively. Glycation levels in both mole-
cules increased on specific lysine residues when the molecules
were incubated at 40C. Low levels of aspartate isomerization and
methionine oxidation were detected at specific sites on 3BNC117
and low levels of isomerization were detected at specific sites on
PGT121. These modifications increased when the molecules were
stressed. Deamidation of asparagine residues on 3BNC117 at sites
HV:144, HV:67, KCnst-Ig:58, and KV:42 increased when the mole-
cule was stressed. Interestingly, when 3BNC117 was coformulated
with PGT121, the hot spots for Asn deamidation on 3BNC117 were
less deamidated compared to the formulation of 3BNC117 alone.
Finally, the detectable clips were quantified for the single formu-
lations and the coformulation (Fig. 8d). All detectible clips
increased when the molecules were stressed. The DP clip at FC-
N:40-Fc-N-41 was the most abundant in each of the single
formulations. When the molecules were coformulated, the clip at
FC-N:40-Fc-N-41 was at a much lower level than was observed in
the single formulations.
MAM analysis was also applied to characterize the dimer
formed when each molecule was formulated separately or when
the molecules were coformulated. Interestingly, when 3BNC117was formulated alone, it formed more dimer when incubated at
40C than PGT121 formulated alone and incubated at the same
temperature (Fig. 5). The rate of dimer formation for 3BNC117 was
3.5X that of PGT121 based on the SEC analysis. MAMwas applied to
the dimer fractions and compared to the monomer fractions to
determine if any modified forms of the molecules were enriched in
the dimer fraction. No specific modifications were enriched in the
dimer fraction of either 3BNC117 or PGT121 when formulated
alone. When the coformulated sample was examined by MAM, a
significant enrichment of 3BNC117-specific peptides was observed
(Supplemental Fig. S3). Conversely, a decrease in the abundance of
PGT121-specific peptides was observed in the dimer fraction. These
data show that the dimer observed in the coformulated sample
consists of approximately 3.5X more 3BNC117 than PGT121, a value
similar to the increased rate of dimer formation for 3BNC117 as
compared to PGT121.
Discussion
Monoclonal Abs (mAbs) are widely used therapeutics for
treatment of several human diseases including cancer and auto-
immune diseases as well as for passive immunization. However,
their effectiveness for the latter is limited against complex anti-
gens/targets due to their mono-specificities for 1 antigen, which
often develop drug resistance, for example, via viral mutations. As a
result, approaches targeting multiple epitopes of the same antigen
or different antigens are increasingly being developed to tackle
drug resistance and to exhibit synergies in neutralizing and cell
killing.56,57 In addition, single shot injections of Abs (incorporating
2 or more mAbs in single injection) are advantageous, particularly
in case where repeated injection of Abs are needed because they
reduce the cost of administrative procedures and improve patient
a
b
Figure 5. Dimer and oligomer (multimer) formation in individual bnAb formulations
and in the coformulation following storage at 40C. Formulations were as described in
Table 1 and stored at 40C for up to 12 weeks. SEC analysis was performed weekly.
Dimer and oligomer were defined based on the elution time of the peaks compared to
the main monomer peak. (a) Percent dimer versus time for all formulations;
(b) % Oligomer versus time for all formulations. 3BNC117 at 100 mg/mL: solid black
squares; 3BNC117 at 50 mg/mL: open black squares; PGT121 at 100 mg/mL: solid red
circles; PGT121 at 50 mg/mL: open red circles; Coformulation of 3BNC117 and PGT121
each at 50 mg/mL: solid green triangles.
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example, pertuzumab and trastuzumab against HER2 (subdomain
II and IV respectively) have shown complementarity in their actions
in preclinical studies.47,58 Several other codelivery approaches with
monoclonal Abs have been explored in recent years.59 For instance,
Symphogen A/S has developed Sym004, which is currently being
evaluated in a clinical trial phase II as a mixture (1:1) of 2 chimeric
IgG1 Abs (mAb992 and mAb1024 against nonoverlapping epitopes
on EGFR to target metastatic colorectal cancer).60 In another study
CL184 antibody cocktail, designed for postexposure prophylaxis
against rabies, was found to be a more optimized product than the
plasma-derived, polyclonal products obtained from rabies-
vaccinated human donors or horses.13,61,62
Since 2010, several broadly neutralizing anti-HIV mAbs target-
ing different epitopes on the viral envelope glycoprotein (Env) have
been isolated from HIV-positive patients29 and multiple clinical
trials have now demonstrated the efficacy of the bnAbs in reducing
viraema in patients.18,19 More recently, studies in nonhuman pri-
mates have shown that combinations of these mAbs targeting
different epitopes showed protection of animals from multiple
SHIV challenges63 and supported the idea of using combinations of
bnAbs as a prophylactic measure to significantly reduce the trans-
mission of AIDS in vulnerable populations. For example, the Bill and
Melinda Gates Foundation and its partners are exploring the use of
this type of therapy for the Sub-Saharan Africa region. Doing so
brings multiple challenges including cost, distribution, cold chains,and importantly, convenience for the patient. One way to increase
convenience and help maintain adherence to the therapy by the
patient is to combine the Abs in a single injection bymanufacturing
and providing the DP in a single vial as a coformulated product.
Coformulation of multiple proteins poses several formulation and
analytical challenges. For example, the increased overall protein
concentration, compared to an individual mAb, and differences in
relative stability in a given formulation buffer, may lead to several
pharmaceutical development challenges including enhanced attrac-
tive intermolecular proteineprotein interactions, increased viscosity,
and compromised structural integrity. These factors can increase the
aggregation propensity of either/both molecules in a coformulation.
Understanding aggregation propensity is a critical aspect during
formulation development of biotherapeutics.32,64 The long-term
stability profile, including the aggregation propensity of the mAbs,
are dependent on structural features of the individual mAb mole-
cules. Hence, development of different analytical methods capable of
assessing the stability of themAb DPs after coformulation is a critical
part of formulation development of comixtures. Assessing stability
and aggregation propensity of individual mAb in a mixture poses
several analytical challenges. Although numerous spectroscopy-
based and separation-based analytical techniques are currently
available forassessingproteinaggregation,65 fewreports are available
on utility of these analytical techniques for studying the stability
profile of complex antibody mixtures.44,45
Preformulation Characterization Studies With the Individual bnAbs
and the Mixture
In this work, 2 broadly neutralizing Abs 3BNC117 and PGT121,
targeting CD4bs and V3-glycan site, respectively, of the HIV gp120
viral protein, were coformulated. Following coformulation, the
stability and degradation profiles of the individual Abs in the
mixture were evaluated. As a first step, DSC and PEG precipitation
assays were employed to evaluate the conformational stability and
apparent solubility of individual bnAbs versus the bnAb mixture.
Because solubility is a critical quality attribute in development of
high concentration protein formulations, it is important to assess
solubility in early stages of formulation design and development.
The PEG precipitation-based methodology was used here for
comparing relative solubility of monoclonal Abs alone and in
mixtures. This assay allows for the rank ordering of Abs based on
their relative solubility without requiring large quantities of pro-
tein.49 Interestingly, PEGmidpt value of the bnAbs mixture (26.4%
PEG) was in between the 2 individual bnAbs (22.1% and 29.0% PEG),
and thus the PEG precipitation assay was able to distinguish be-
tween the 3 samples with the mixture behaving as a composite of
the 2 individual components. The lower solubility of the PGT121
may be due to an increase in exposed hydrophobic surfaces as
compared to 3BNC117. For example, Standup Monolayer Affinity
Chromatography differentiates molecules based on hydrophobici-
ty66 showed a longer retention time for PGT121 as compared to
3BNC117 further supporting an increased exposure of hydrophobic
surfaces for the antibody (data not shown).
Differential scanning calorimetry has been a widely utilized
technique to characterize protein conformational stability during
formulation development. It has also been used to analyze complex
protein mixtures including human plasma and as a check of the
physical stability of proteins in mixtures.67,68 For example, in a
study involving thermal denaturation of mixtures of a-lactalbumin
(a-lac) and b-lactoglobulin (ß-lg), the mixture showed 2 thermal
transitions at 37.5C and 69.1C (corresponding to the denaturation
of apo-a-lac and ß-lg, respectively) with a shoulder at approxi-
mately 63C (corresponding to the denaturation of holo- a -lac).
Moreover, in a mixture, thermal transition temperature of apo-a
Figure 6. Quantification of clipped species in bnAb formulations in ASu from representative electropherograms as measured by reduced SDS CE. Formulations stored at 40C for 12
weeks showed an increase in low molecular weight species migrating before the heavy chain and light chain peaks. Heterogeneity of the 3BNC117 light chain resulted in comi-
gration of some degradation species with the main peaks in the coformulated samples. See Table 1 for composition of formulations. (a) Bio-Rad SDS-MW size standards: 10, 20, 35,
50, 100, 150, and 225 kDa, (b) 3BNC117, (c) PGT121, (d) 3BNC117 and PGT121 mixture. Black lines are for time 0 samples and red lines are after 12 weeks storage at 40C.
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Figure 7. Quantification of clipped species formed over time in ASu formulations stored at 40C as measured by reduced SDS CE. Lowmolecular weight species were grouped based
on migration time relative to the heavy and light chain peaks, pre light chain species migrating before light chain, and mid molecular weight species migrating between the light
and heavy chain peaks. Data plotted is based on a single analysis at each time point. 3BNC117 at 100 mg/mL: solid black squares; PGT121 at 100 mg/mL: solid red circles;
Coformulation of 3BNC117 and PGT121 each at 50 mg/mL: solid green triangles. An error up to 0.7% was estimated using the standard error of the line regression analysis. See
Table 1 for composition of formulations. (a) Percent purity vs. time, (b) percent pre light chains peaks, (c) percent mid molecular weight peaks, (d) percent total clips.
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in a mixture thermal stability of a -lactalbumin increased while
stability of ß -lactoglobulin decreased.69 In this study examining
the DSC thermal profile of the bnAb mixture, 2 major transitions
were observed, which were overlapped with major endothermic
peak of individual bnAbs. In addition, the Tm values for each peak
in the mixture were also correlated to Tm values of individual
bnAbs. This result demonstrated that conformational stability of
the bnAbs in the mixture is not significantly different from the
individual bnAbs, and thus there are no notable destabilizing in-
teractions between the 2 bnAbs when coformulated.
Stability Studies With the Individual bnAbs and the Mixture to
Monitor Aggregation Propensity
Aggregation is a major degradation pathway of mAbs, which is a
concern during formulation development because aggregates can
lower or increase potency as well as potentially trigger detrimental
antidrug immunogenic responses on administration.70 Under
stressed storage conditions, partial unfolding of antibody domains
can occur, leading to self-association followed by nucleation and
growth of aggregates.71 Both Fab and Fc structures within individual
mAbs have aggregation-prone regions,72 and the overall rate of ag-
gregation is also affected by solution conditions (e.g., pH, ionic
strength, excipients) and the stress exposure conditions (e.g., tem-
perature, agitation, freeze thaw).73,74 Thus, a combination of external
experimental conditions can affect aggregation propensities of Abs,
as well as the intrinsic antibody properties (i.e., primary sequence
and structural conformation).71 One of our primary interests in this
study was to better understand the aggregation behavior of bnAbs
when stored alone or in combination at elevated temperatures.
Size exclusion chromatography has been used extensively to
monitor aggregation propensity and comparing stability of mono-
clonal Abs.75 Interestingly, a different aggregation profile was
observed in the individual bnAbs. In addition, accelerated stability
studies monitoring mAb dimer and multimer formation by SE-HPLCanalysis showed that the 3BNC117 primarily formed dimer species,
whereas PGT121 primarily formed multimer species at elevated
temperatures (see Figs. 4 and 5). Each of the species is in part due to
nonreducible crosslinking as evidenced by the aggregation-related
peaks in the reduced CE-SDS profiles. In the mixture, the rates of
dimer and multimer formation were significantly lower than those
expected for either protein at 100 mg/mL but were similar to the
rates for the individual proteins at 50 mg/mL. This result suggests
that the presence of each antibody does not influence the aggrega-
tion profile of the other antibody and that the proteins in themixture
aggregated as if they were formulated separately. In support of this
possibility, the conformational and colloidal stability data from the
DSC and PEG solubility studies as discussed above suggest the
PGT121 is less soluble than 3BNC117. Isolation of the dimer species
and interrogation by theMAM technique showed that the dimerwas
primarily 3BNC117 as would be expected if the proteins did not form
coaggregates, albeit we cannot fully discard this hypothesis without
additional experimentation. More work is underway to determine if
the primary amino acid sequence or posttranslational modifications
of 3BNC117 predisposes it to dimer formation and if the primary
sequence of PGT121 predisposes it to multimerization.
The results of our studies are consistent with similar conclusions
reached by Chen et al.44 for mixtures of multiple Abs stored under
stress conditions. In their studies, 3 different Abs were mixed,
heated to 70C for 10 min, and the soluble fraction quantified by
cation-exchange chromatography. Only one mAb precipitated
while the other 2 remained soluble, and these results correlated to
their melting temperature values. The authors concluded that “Our
CEX52 results for the IgG1-A, IgG2-A, and IgG2-B mixture were
surprisingly similar to the individual mAb data, suggesting little
interference between the molecules.” Woodard et al.45 made
similar observations in mixtures of up to 8 Abs.
Together, these data suggest that this may be a general phenom-
enon inmixtures of Abs and leading to thequestion ofwhy theAbs do
not form multimeric antibody complexes? For 3BNC117 and PGT121,
the Fc regions are indistinguishable pointing toward the stability
Figure 8. Comparison of relative quantification of posttranslational modifications and clips for 3BNC117, PGT121, and coformulated 3BNC117 þ PGT121 at control conditions and
stress conditions (12 wk at 40C). (a) Comparison of deamidation, glycation, isomerization, and oxidation at common amino acid sites shared between each of the bnAb molecules/
formulations. (b) Comparison of deamidation, glycation, isomerization, and oxidation at amino acid sites that are specific to 3BNC117. (c) Comparison of glycation and isomerization
at amino acid sites that are specific to PGT121. (d) Comparison of clipping at common sites between all of the molecules (Fc-N:40-Fc-N:41, Fc-N:9-Fc-N:10, Hinge:111-Hinge:112, and
Hinge:108-Hinge:109), sites specific to 3BNC117 (HV:83-HV:84 and HV:85-HV:86), and sites specific to PGT121 (LmdV:142-LmdV:143).
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Figure 9. Structure models were generated from PDB files for 3BNC11776 (PDB ID: 4JPV) and PGT12177 (PDB ID: 4FQ1) using PyMol (The Pymol molecular graphics system, version 1.8
Schr€odinger, LLC) modeling software and show 3BNC117 and PGT121 Fv with highlighting of the CDR of the heavy and light chains. The heavy chain CDR3 is colored dark cyan. The
hydrophobic residues of PGT121 HC_CDR3 are colored red. The rest of the coloring scheme is as follows: HC_CDR1 is blue, HC_CDR2 is dark orchid, HC_CDR3 is dark cyan, LC_CDR1 is
dodger blue, LC_CDR2 is medium purple, and the LC_CDR3 is cyan. The sequence with annotations can be found in the supplementary material (Supplemental Figs. S4-S6).
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structures clearly demonstrate differences between the Fv regions
(Fig. 9) of the Abs such that structural interference may only allow
association of like Abs and direct formation to either the dimer or
multimer forms. PGT121which formedprimarilymultimers, alsohad
a much lower relative apparent solubility in PEG as compared to
3BNC117, suggesting the possible presence of an accessible hydro-
phobic patch on the surface that promotes proteineprotein in-
teractions. Comparison of PGT121 to 3BNC117 structures (Fig. 9)
shows an extended CDR domain, HCDR3, on PGT121 forming a hy-
drophobic cluster with Phe at the tip and Trp and Tyr residues
comprising the sides. The DSC data suggest a lower thermal stability
for the PGT121 Fab. We hypothesize that at 40C, the flexibility in-
creases such that the hydrophobic residues lining the extended
HCDR3 domain and possibly the LC/HC interface are more accessible
and periodically reduces the steric hindrance of this region to the
hydrophobicCDR spike allowing for interactionbetweenneighboring
proteins and forming a stable multimeric complex. Multimer for-
mation by PGT121 at 30Cwas not observed further suggesting that a
thermal transition occurs between 30C and 40C for the protein
leading to the increased flexibility. By this reasoning, 3BNC117would
not be expected to form multimers due to the increased enthalpic
stability of its Fab region. If the lack of coaggregation holds for lower
temperature storage over longer times, then this would also provide
support to the hypothesis that antibody-antibody interactions have a
degree of specificity, and that this specificity allows us to use data
from singly formulated Abs to predict stability in coformulated
solutions.
Stability Studies With the Individual bnAbs and the Mixture to
Monitor Chemical Stability
To further characterize the nature and levels of chemical mod-
ifications and degradation products, the MAM was employed. The
MAM leverages high mass accuracy/high resolution MS data
generated by Orbitrap technology and automated identification
and relative quantification of posttranslational modifications with
dedicated software.48 The bnAb samples were analyzed by MAM to
quantify the formation of posttranslational modifications formed
during storage at accelerated temperature. Chemical modifications
such as isomerization, deamidation, oxidation, and glycation of
proteins can play an important role in the protein aggregation
pathway.78,79 In this work, isomerization in the hinge region was
the most abundant modification observed in each of the bnAbsamples with the highest levels in the PGT121 samples. Aspartate
residues in the hinge region are highly susceptible to isomerization
under accelerated storage conditions, and it is favored when
formulation conditions are mildly acidic.80 In contrast to PGT121, a
relatively higher amount of oxidation and deamination was
observed in 3BNC117. Interestingly, when 3BNC117 and PGT121
were coformulated, the amount of deamidation at HV:144 and
KCnst-Ig:58, of 3BNC117, was significantly reduced. These data
suggest that the asparagine residues at HV:144 and KCnst-Ig:58 are
protected from deamidation in the coformulated samples. Each
formulation was fractionated to enrich for the dimer/multimer and
the monomer to better understand the possible role these PTMs
play in aggregation. The PTM profiles for the single molecule for-
mulations and the coformulation were similar in the dimer/mul-
timer versus the monomer. Interestingly, as described above, the
dimer/multimer fraction, in the coformulated sample, was enriched
for 3BNC117-specific peptides. These data suggest that the dimer/
multimer in coformulated sample is made up of mostly 3BNC117,
and none of the PTMs monitored appear to be playing a role in the
formation of the aggregates.
Another important aspect of protein stability is backbone hy-
drolysis, or clipping, which is typically quantified by SEC analysis
under native-like conditions and by CE-SDS under reduced and
denaturing conditions. Although SEC analysis shows an increase
in clip species (see Fig. 4), this technique may underreport the
total percent when only a single clip occurs, and the peptides are
held in place by disulfide bonds. Reduced CE-SDS ameliorates this
problem and allows for quantitation by UV detection. In the case
of 3BNC117, the LC migrates anomalously due to glycosylation of
Asn90, confounding the analysis when both PGT121 and 3BNC117
are coformulated. In that case, clips from the 3BNC117 LC can
comigrate with the PGT121 LC. This potential problem can be
circumvented by using the MAM to quantify the level of clipping
in the sample. MAM analysis has the added benefit of defining the
exact site(s) of hydrolysis for each of the Abs in the mixture.
Although both molecules have similar sites of clipping, 3BNC117
shows increased susceptibility of the DP site between Fc:N-40 and
Fc:N-41 when formulated individually but not in the coformu-
lated mixture. The reason for this reduction is not clear and we
are endeavoring to define the mechanism through which this may
occur.
In addition, glycation was observed in the individual bnAb
formulations as well as in the mixture when stored at higher
temperature. Glycation is a condensation reaction between the
A. Patel et al. / Journal of Pharmaceutical Sciences 107 (2018) 3032-3046 3045aldehyde groups of reducing sugars and the primary or the sec-
ondary amines of proteins, in particular at lysine residues. In
liquid formulations, sucrose is a commonly used protein stabi-
lizer; however, it can hydrolyze into the reducing sugars glucose
and fructose (especially at elevated temperatures and acidic so-
lution pH), which can cause glycation in proteins. Glycation can
affect protein structure, functionality, and therapeutic potential of
proteins.79,81 Therefore, characterization and quantification of
glycation in protein-therapeutics is crucial. However, identifica-
tion and characterization of glycation in therapeutic mAbs can be
challenging due to multiple glycation prone sites. In individual
bnAb as well as mixture samples, when stored at 40C, glycation
was observed in Fc region, hinge region, and LC constant region.
More glycation sites of Lys specific in the Fc region were observed
in 3BNC117 compared to PGT121. Low levels of glycation were
observed in all of the samples stored at 4C for the same period of
time (data not shown). Glycation of Abs at higher temperatures
has been reported in the previous studies when formulation
buffer contained sucrose.79,81 In a study by Gadgil et al., IgG for-
mulations containing sucrose showed glycation in lysine residues
when stored at 29C and 37C. Moreover, the rate of glycation
increased incrementally with increasing temperature and time,
and no glycation was observed in sample stored at 4C for 18
months.81
Conclusions
Although several recent studies demonstrated increasing
needs for antibody combination formulations due to synergistic
effects and improvements in efficacy, there is limited literature
available on the pharmaceutical stability of individual Abs in
coformulations. Such stability evaluation requires the use of
stability-indicating analytical techniques able to differentiate
individual Abs in a mixture. Our study provides insight into
coformulation of 2 broadly neutralizing Abs and evaluated the
physicochemical stability of coformulated Abs under both real
time and stressed conditions. Many of the analytical methods
employed in the study were able to monitor the structural
integrity of both molecules within the mixture. The results
demonstrated that in general, no physical interaction was
observed between the 2 Abs in the mixture, but there were some
notable effects on some of the Asn deamidation rates. Overall, the
results presented herein highlight a case study of monitoring the
physicochemical stability of monoclonal antibody mixtures and
the power of combining multiple analytical techniques to cover
key structural attributes of the molecules, which allows the
screening of a codelivery system of Abs with desired stability
characteristics. For example, the long term goal of providing
stable, low cost liquid formulations containing a mixture of
bnAbs for worldwide use will require ensuring stability during
manufacturing, storage, transport, and administration, a similar
stability challenge currently being addressed for vaccines
distributed worldwide in the vaccine cold chain.82
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